medigraphic.com
ISSN 3122-3893 (Electronic)

2026, Number 2

<< Back Next >>

Rev Mex Traspl 2026; 15 (2)

Six-year experience in the detection of BK virus infection by viruria in patients with acute renal graft dysfunction

Toledo-Sotelo JI, Rodríguez-Villanueva FL, Ortega-Rodríguez R, Rodríguez-Garduño LS, Espinoza-Pérez R, Benítez-Arvizu G, Cancino-López JD, 4Delgado-Colín G, Martínez-Mendoza ME, Bautista-Olayo R, Aranda-Osorio JR, Hernández-Rivera JCH

Language: Spanish
References: 22
Page: 61-67
PDF size: 832.12 Kb.


ABSTRACT

Introduction: infections continue to be one of the main complications in kidney transplantation (KT) and are directly related to the duration of the KT and a cause of morbidity and mortality. The objective is to show the incidence of BK virus cases due to viruria. Material and methods: a descriptive study was conducted of viruria studies in patients within the acute graft dysfunction (AGD) protocol. Patients were included from February 2019 to December 2024, with those with 107 copies considered positive. Descriptive statistics were performed with frequencies and percentages for qualitative variables and categorization of results. The SPSS version 26 statistical package was used. Results: 521 viruria tests were performed on patients enrolled in the ICD protocol. Twenty-two patients (4.22%) were positive, 421 patients (80.81%) were not detected, and 78 patients (14.97%) were detected without a positive criterion, ranging from 100 to fewer than 10 million copies. Conclusions: BK virus infection detected by viruria represented 4.22% of the total transplant patients studied by ICD. This type of testing allows for early detection and the implementation of measures that improve the prognosis for graft function. Hospitals that perform this type of testing must be equipped with the appropriate equipment and specialized personnel, as well as the knowledge of the associated risk factors in each case. Decoy cell cytology can be an alternative for those who do not have viruria and/or viremia at their centers.


REFERENCES

  1. Gardner SD, Field AM, Coleman DV, Hulme B. New humanpapovavirus (B.K.) isolated from urine after renal transplantation.Lancet. 1971; 1 (7712): 1253-1257. doi: 10.1016/s0140-6736(71)91776-4. Available in: https://es.wikipedia.org/wiki/Virus_BK#cite_note-2

  2. Kant S, Dasgupta A, Bagnasco S, Brennan DC. BK virusnephropathy in kidney transplantation: a state-of-the-art review.Viruses. 2022; 14 (8): 1616. doi: 10.3390/v14081616.

  3. Wadei HM, Rule AD, Lewin M et al. Kidney transplantfunction and histological clearance of virus following diagnosisof polyomavirus-associated nephropathy (PVAN). Am JTransplant. 2006; 6 (5 Pt 1): 1025-1032. doi: 10.1111/j.1600-6143.2006.01296.x.

  4. Knowles WA, Pipkin P, Andrews N et al. Population-based studyof antibody to the human polyomaviruses BKV and JCV and thesimian polyomavirus SV40. J Med Virol. 2003; 71 (1): 115-123.doi: 10.1002/jmv.10450.

  5. Prelog M, Egli A, Zlamy M, Hirsch HH. JC and BK polyomavirusspecificimmunoglobulin G responses in patients thymectomizedin early childhood. J Clin Virol. 2013; 58 (3): 553-558. doi:10.1016/j.jcv.2013.08.035.

  6. Chong S, Antoni M, Macdonald A, Reeves M, Harber M, MageeCN. BK virus: Current understanding of pathogenicity andclinical disease in transplantation. Rev Med Virol. 2019; 29 (4):e2044. doi: 10.1002/rmv.2044.

  7. Schwarz A, Linnenweber-Held S, Heim A, Framke T, HallerH, Schmitt C. Viral origin, clinical course, and renal outcomesin patients with bk virus infection after living-donor renaltransplantation. Transplantation. 2016; 100 (4): 844-853. doi:10.1097/TP.0000000000001066.

  8. Hirsch HH, Knowles W, Dickenmann M et al. Prospective studyof polyomavirus type BK replication and nephropathy in renaltransplantrecipients. N Engl J Med. 2002; 347 (7): 488-496. doi:10.1056/NEJMoa020439.

  9. Babel N, Fendt J, Karaivanov S et al. Sustained BK viruriaas an early marker for the development of BKV-associatednephropathy: analysis of 4128 urine and serum samples.Transplantation. 2009; 88 (1): 89-95.

  10. Maung MT, Chong CH, von Huben A et al. Serum and urinenucleic acid screening tests for BK polyomavirus-associatednephropathy in kidney and kidney-pancreas transplant recipients.Cochrane Database Syst Rev. 2024; 11 (11): CD014839. doi:10.1002/14651858.CD014839.pub2

  11. Nankivell BJ. The accuracy of blood nucleic acid testingto predict bk polyomavirus nephropathy varies by clinicalcontext. Transplant Direct. 2025; 11 (10): e1845. doi: 10.1097/TXD.0000000000001845.

  12. Nankivell BJ, Renthawa J, Sharma RN, Kable K, O’ConnellPJ, Chapman JR. BK virus nephropathy: histological evolutionby sequential pathology. Am J Transplant. 2017; 17 (8): 2065-2077. doi: 10.1111/ajt.14292.

  13. Kotton CN, Kamar N, Wojciechowski D et al. The secondinternational consensus guidelines on the management of BKpolyomavirus in kidney transplantation. Transplantation. 2024;108 (9): 1834-1866. doi: 10.1097/TP.0000000000004976.

  14. ELITech Group S.p.A. Manual de Instrucciones: ELITe InGenius,software versión 1.3 (Ref. SCH-Mint030_08_es). 2022. Available in:https://www.elitechgroup.com/documentation/wp-content/uploads/sites/30/2022/12/SCH-mINT030_08_es_compressed.pdf

  15. Hodowanec AC, Simon DM. BK virus screening and managementpractices in US kidney transplant programs: a survey. TransplInt. 2015; 28: 1339-1341. doi: 10.1111/tri.12602.

  16. Zakaria ZE, Elokely AM, Ghorab AA, et al. Screening for BKViremia/Viruria and the Impact of Management of BK VirusNephropathy in Renal Transplant Recipients. Exp Clin Transplant.2019;17(Suppl 1):83-91. doi:10.6002/ect.MESOT2018.O17.

  17. Kraivisitkul N, Noppakun K, Sakuludomkan C et al. Theassociation between serum tacrolimus concentrations and BKviruria in kidney transplant recipients. Sci Rep. 2025; 15 (1):2872. doi: 10.1038/s41598-025-86465-2.

  18. Eder M, Kainz A, Omic H et al. A systematic literature reviewand meta-analysis evaluated modifiable risk factors for thedevelopment of BK polyoma virus-associated complications.Kidney Int. 2025; 108 (4): 669-685. doi: 10.1016/j.kint.2025.06.014.

  19. Burek KM, Ivkovic V, Kovacevic Vojtusek I, Zunec R. The role ofHLA and KIR Immunogenetics in BK virus infection after kidneytransplantation. Viruses. 2020; 12 (12): 1417. doi: 10.3390/v12121417.

  20. Bohl DL, Storch GA, Ryschkewitsch C et al. Donor origin of BKvirus in renal transplantation and role of HLA C7 in susceptibilityto sustained BK viremia. Am J Transplant. 2005; 5 (9): 2213-2221. doi: 10.1111/j.1600-6143.2005.01000.x.

  21. Kavuzlu M, Bastürk B, Atac FB, Aliskan HE, Kantaroglu B.Investigation of the relationship between BK virus and humanleukocyte antigens in kidney transplant recipients. Exp ClinTransplant. 2020; 18 (Suppl 1): 51-54. doi: 10.6002/ect.TONDTDTD2019.O24.

  22. Liu Y, Kong C, Hu H et al. Risk factors for BK virus infection inDCD donor kidney transplant recipients. Front Med (Lausanne).2023; 10: 1181743. doi: 10.3389/fmed.2023.1181743.




2020     |     www.medigraphic.com